TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB [clinicaltrials:NCT00023348]

Bio2RDF uri

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB [clinicaltrials:NCT00023348]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00023348

Bio2RDF identifier

NCT00023348

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00023348

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00023348

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:4c3cb4f1b6774aae040152e2cdb4237b

brief summary [clinicaltrials_vocabulary:brief-summary]

Primary Objectives: ...... obtained in the parent trial.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To determine the proportion of patients with HIV-related tuberculosis who have abnormal pharmacokinetics of isoniazid and rifabutin. [clinicaltrials_resource:808fc6bb8c8c6560b77b442e47f3c987]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To determine the proportion of patients with HIV-related tuberculosis who have abnormal pharmacokinetics of isoniazid and rifabutin. [clinicaltrials_resource:014d964a25f87d212cdd62330af25d86]

To determine the proportion of patients with HIV-related tuberculosis who have abnormal pharmacokinetics of isoniazid and rifabutin. [clinicaltrials_resource:13f8ce92fe515d4a2059cab33121033a]

To determine the proportion of patients with HIV-related tuberculosis who have abnormal pharmacokinetics of isoniazid and rifabutin. [clinicaltrials_resource:5d8bab77b4504a834519060325eab0c6]

To determine the proportion of patients with HIV-related tuberculosis who have abnormal pharmacokinetics of isoniazid and rifabutin. [clinicaltrials_resource:6220ab71e6472e80cccb1a06b687f793]

collaborator [clinicaltrials_vocabulary:collaborator]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

completion date [clinicaltrials_vocabulary:completion-date]

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

This study will seek to ...... he start of rifabutin).

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00023348 [clinicaltrials_resource:66b12ab37aa987b9c416cef2d01c0e4c]

enrollment [clinicaltrials_vocabulary:enrollment]

150

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2001-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

intervention [clinicaltrials_vocabulary:intervention]

Isoniazid [clinicaltrials_resource:00043d62bb3be560814eaee270d03523]

Rifabutin [clinicaltrials_resource:79a4745cac85ba5674a29f920822f23a]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Rifabutin [clinicaltrials_resource:0873c60740b3276b384569eae4aec237]

Isoniazid [clinicaltrials_resource:b47e0083d86e6576a506df1304d91881]

keyword [clinicaltrials_vocabulary:keyword]

http://www.w3.org/2001/XMLSchema#string

Tuberculosis

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2005-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

link [clinicaltrials_vocabulary:link]

Click here for more information about the Tuberculosis Trials Consortium (TBTC) [clinicaltrials_resource:933cff17ea172c799256c7e5eaef4f6d]

location [clinicaltrials_vocabulary:location]

Central Arkansas Veterans Health System [clinicaltrials_resource:2f65639d5c452009e9e6b9ae4a532f06]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00023348

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

TBTC Study 23A: Pharmacokineti ...... sing a Rifabutin-Based Regimen

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CDC-NCHSTP-2173

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Marc Weiner, MD [clinicaltrials_resource:5bb4bfceb771aa45a5cd851f74e4b4cd]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Federal Government [clinicaltrials_resource:9ec796ce4ab23acc2803e9275f0c0f85]

phase [clinicaltrials_vocabulary:phase]

Phase 2/Phase 3 [clinicaltrials_resource:d4235ce98efbb8b69dded131ccb7fa52]

secondary id [clinicaltrials_vocabulary:secondary-id]

23A

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Centers for Disease Control and Prevention [clinicaltrials_resource:9bf9dd4a92652d24bc69b64f4927b75f]

start date [clinicaltrials_vocabulary:start-date]

1999-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00023348 study design [clinicaltrials_resource:48aa35c5af1addc6435237e3fe931748]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00023348

verification date [clinicaltrials_vocabulary:verification-date]

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00023348

http://www.w3.org/2001/XMLSchema#string

title

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

TBTC Study 23A: Pharmacokineti ...... B [clinicaltrials:NCT00023348]

@en